About Aeglea
Aeglea is a company based in Austin (United States) founded in 2013. Aeglea has raised $56 million across 4 funding rounds from investors including KBI Biopharma, TD Securities and Orbimed. The company has 81 employees. Aeglea offers products and services including Antibodies, Therapeutic Combinations, and Precision Immunology Approaches. Aeglea operates in a competitive market with competitors including Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Austin, United States
- Employees 81
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website aeglea.com
- Social LinkedIn X
- Legal Name Aeglea Biotherapeutics, Inc.
- Total Equity Funding$56M (USD)
in 4 rounds
- InvestorsKBI Biopharma
& 11 more
- Employee Count81
Products & Services of Aeglea
Aeglea offers a comprehensive portfolio of products and services, including Antibodies, Therapeutic Combinations, and Precision Immunology Approaches.
Develops advanced antibodies for treating IBD and immune diseases with improved efficacy.
Creates rational combinations to enhance dosing and outcomes for immune-mediated conditions.
Applies precision methods to develop targeted therapies for IBD and related diseases.
Funding Insights of Aeglea
Aeglea has successfully raised a total of $56M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56M
- Total Rounds 4
- First Round $12M
(Dec 2013)
- Investors Count 12
All 4 funding rounds of Aeglea with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | – | Series B | – | Austin Technology Incubator | – |
| Mar 2015 | $44M | Series B | – | Lilly Ventures, Novartis Venture Fund | |
| Jun 2014 | – | Series A | – | Hunter Trust | – |
| Dec 2013 | $12M | Series A | – | UT Horizon Fund, Novartis Venture Fund | – |
12 investors in total: 12 institutional.
Investors in Aeglea
Aeglea has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include KBI Biopharma, TD Securities and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Deep tech commercialization is facilitated by Austin Technology Incubator. | 1989 | ati.utexas.edu | Austin, USA | |
Early-stage life sciences investments are targeted in the healthcare sector. | – | lillyventures.com | Indianapolis, United States | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
A family investment office based in Minneapolis, USA, is operated. | – | huntertrust.com | Minneapolis, USA | |
- | – | uthorizons.com | - | |
Offers asset management and advisory for equities and fixed income portfolios. | 1969 | jennison.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Aeglea
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aeglea
1 people are tracked at Aeglea (1 in leadership); the tracked headcount is 81.
| Name | Role | Group |
|---|---|---|
Anthony Quinn | CEO & President | Leadership |
Complete people profiles for Aeglea
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aeglea
3 dated milestones of Aeglea across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Aeglea is founded.
- Funding First funding round of $12.0M.
- Funding Latest funding round, Series B,.
Competitors of Aeglea
Aeglea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ultragenyx, Alnylam, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. | |
| homologymedicines.com | 2015 | Lexington, United States | $127M | 221 | Developer of gene therapies for rare genetic diseases | |
| immusoft.com | 2009 | Seattle, United States | $44.13M | – | B cells are programmed as biofactories for therapeutic protein delivery. | |
| pharvaris.com | 2015 | Leiden, Netherlands | $164.21M | – | Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema. | |
| proqr.com | 2012 | Leiden, Netherlands | $57.99M | – | RNA-based therapeutics are developed for genetic retinal disorders. |
Detailed competitors of Aeglea
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aeglea
The website of Aeglea (aeglea.com) receives about 2.9K visits a month and ranks #5,863,997 among all websites worldwide, #6,287 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▲ 0.8% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,863,997
among all websites
- Category rank#6,287
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.6
- Average visit8 sec
- DevicesDesktop 30% · Mobile 70%
Latest news on Aeglea
Complete news archive for Aeglea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Aeglea
10 companies that operate in the same segment as Aeglea (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aeglea
Aeglea was founded in 2013.
Aeglea is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Anthony Quinn is the current CEO of Aeglea.
Aeglea is a funded company, having raised a total of $56M across 4 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on Dec 2013.
Aeglea has 81 employees.
Aeglea was founded in 2013 in Austin, United States, within the biotechnology sector. Focus is placed on developing enzyme-based therapies for rare metabolic disorders. Key programs include Pegzilarginase, which reduces arginine levels in Arginase 1 Deficiency patients, AGLE-177 for cystathionine beta-synthase deficiency, and a candidate for Cystinuria. Human enzymes are engineered as therapeutic catalysts to address chemical imbalances associated with these conditions. Operations center on clinical advancement and regulatory pathways.
Aeglea's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
Aeglea offers Antibodies, Therapeutic Combinations, and Precision Immunology Approaches.
Aeglea has 12 investors. Key investors include KBI Biopharma, TD Securities, Orbimed, RA Capital, and Austin Technology Incubator.
Aeglea operates through Aeglea Biotherapeutics, Inc..